Clinical Information for Ajovy (fremanezumab)

About Ajovy (fremanezumab)

This page provides supplemental information for the Ajovy (fremanezumab) dosing calculator. Ajovy is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) ligand and is indicated for the preventive treatment of migraine in adults. It is administered via subcutaneous injection.

Calculator Outputs

The primary output of this tool is the next recommended administration date. The calculation is based on the selected dosing regimen and the date of the last administered dose. The tool provides a date for either the next monthly or quarterly injection schedule.

How to Use the Calculator

To determine the next dose date, follow these steps:

• Select Dosing Regimen: Choose between “Monthly Dosing (225 mg)” or “Quarterly Dosing (675 mg)” based on the patient’s current prescription.
• Enter Last Dose Date: Using the date picker, input the exact date the last dose of Ajovy was administered.
• Calculate: Click the “Calculate Next Dose” button to see the projected date for the next administration.

Dosing Overview

Ajovy offers two subcutaneous dosing options for migraine prevention, which do not require a loading dose:

• Monthly Dosing: 225 mg administered once a month.
• Quarterly Dosing: 675 mg administered once every three months. The quarterly dose is given as three consecutive 225 mg injections.

The choice of dosing regimen can be tailored to patient preference and clinical judgment.

Switching Dosing Regimens

Patients can be switched from a monthly to a quarterly regimen, or vice versa. When switching, the first dose of the new regimen should be administered on the next scheduled dosing day. For example, a patient on a monthly schedule can receive their first quarterly dose on the date their next monthly dose was due.

Missed Dose

According to the official Prescribing Information, if a dose of Ajovy is missed, it should be administered as soon as possible. Following this dose, the administration schedule (monthly or quarterly) should be re-established from the date of the most recent injection.

Safety Alerts

The most common adverse reactions (≥5% and greater than placebo) are injection site reactions. Hypersensitivity reactions, including rash, pruritus, and urticaria, have been reported. Anaphylaxis and angioedema can occur. Patients should be advised to seek immediate medical attention if they experience symptoms of a serious hypersensitivity reaction. This information is not exhaustive; always consult the full Prescribing Information for a complete list of warnings and precautions.

Frequently Asked Questions

What does the Ajovy dosing calculator do?

The calculator determines the next scheduled administration date for Ajovy based on whether the patient is on a monthly (add 1 month) or quarterly (add 3 months) dosing schedule from their last injection date.

Does this tool account for the initial dose?

Yes, the calculation is based on the “last administered dose date,” which can be the initial dose or any subsequent dose. Ajovy does not require a loading dose.

What if I enter a date in the future?

The tool is designed to use past dates. The date input is typically restricted to the current day or earlier to prevent calculating from a dose that has not yet been given.

Can I use this calculator to switch a patient from monthly to quarterly dosing?

Yes. Enter the last monthly dose date and select the “Quarterly Dosing” regimen. The tool will calculate the date for the first 675 mg dose, which would be three months after the last 225 mg dose, aligning with prescribing guidelines for switching.

What is the recommended dose of Ajovy for migraine prevention?

The recommended dosage is either 225 mg subcutaneously once monthly or 675 mg subcutaneously once every 3 months.

How is the 675 mg quarterly dose of Ajovy administered?

The 675 mg dose is administered as three separate, consecutive 225 mg subcutaneous injections.

What should a patient do if they miss their Ajovy injection?

The patient should take the missed dose as soon as they remember. The next dose should then be scheduled based on the new administration date, restarting the monthly or quarterly interval from that point.

Is there a difference in efficacy between the monthly and quarterly regimens?

Clinical trials have shown that both the monthly and quarterly dosing regimens of Ajovy are effective in reducing monthly migraine days compared to placebo. The choice of regimen often comes down to physician and patient preference.

References

• AJOVY (fremanezumab-vfrm) injection, for subcutaneous use – Full Prescribing Information. U.S. Food and Drug Administration.
• Drugs@FDA: FDA-Approved Drugs – Ajovy. U.S. Food and Drug Administration.
• Dosing & Administration | AJOVY® (fremanezumab-vfrm) HCP. Teva Pharmaceutical Industries Ltd.
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2018;319(19):1999–2008.